MALVERN, Pa., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will participate in a fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020.
See the article here:
Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
Related Post
- Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 12th, 2021
- GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial - January 12th, 2021
- GenMark Diagnostics Provides Preliminary Operational and Financial Results for 2020 - January 12th, 2021
- Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene - January 12th, 2021
- INCB001158 Biliary Tract Cancer Data to be Presented at 2021 Virtual ASCO Gastrointestinal Cancers Symposium - January 12th, 2021
- IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant - January 12th, 2021
- Mesoblast Presents Heart Failure Phase 3 Trial Results at Investor Healthcare Conference - January 12th, 2021
- Generation Bio Announces Closing of Public Offering - January 12th, 2021
- T2 Biosystems T2SARS-CoV-2™ Panel Proves Effective Amid Global Rise in Variants of the SARS-CoV-2 Virus - January 12th, 2021
- Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units - January 12th, 2021
- Qilian International Holding Group Limited Announces Pricing of Initial Public Offering - January 12th, 2021
- Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common... - January 12th, 2021
- Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health - January 12th, 2021
- Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study - January 12th, 2021
- Addex to Present at the Baader Helvea Swiss Equities Conference - January 12th, 2021
- iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19 - January 12th, 2021
- BetterLife Provides Shareholder Update and 2021 Product Development Roadmap - January 12th, 2021
- Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19 - January 12th, 2021
- Recommendation by the Nomination Committee concerning the Board of Directors to be elected by the 2021 AGM of Orion Corporation - January 12th, 2021
- Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities - January 12th, 2021
- Altimmune to Present at the 4th Annual NASH Summit 2020 Digital Conference - December 11th, 2020
- New Study Provides Personalized Breast Cancer Risk Information for Women with ATM Gene Mutations - December 11th, 2020
- Lexicon Pharmaceuticals Receives Fast Track Designation From the FDA for LX9211 for Diabetic Peripheral Neuropathic Pain - December 11th, 2020
- Arch Therapeutics to Present at the 13th Annual LD Micro Main Event Conference - December 11th, 2020
- ExCellThera receives Priority Medicines (PRIME) designation from European Medicines Agency for ECT-001 Cell Therapy - December 11th, 2020
- Cynata Secures $15m Placement Led By $10m from Healthcare Investor BioScience Managers to Expand Development Pipeline - December 11th, 2020
- Financial calendar for Zealand Pharma in 2021 - December 11th, 2020
- Galecto Reports Third Quarter 2020 Operating & Financial Results and Provides a Corporate Update - December 11th, 2020
- New sales reporting structure introduced. 2020 organic sales growth outlook now expected at 0%, from previously -2% to +2% - December 11th, 2020
- Rhythm Pharmaceuticals Announces Appointments of Camille L. Bedrosian, M.D., and Lynn Tetrault, J.D., to its Board of Directors - December 11th, 2020
- Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome - December 11th, 2020
- SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the... - December 11th, 2020
- CHMP recommends approval of Plavix® (clopidogrel) with aspirin in adults for certain types of strokes - December 11th, 2020
- Akari Therapeutics Announces New Clinical Data that Show Long-Term Self-Administered Nomacopan is Well-Tolerated and Substantially Reduces Transfusion... - December 11th, 2020
- Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress - December 11th, 2020
- AskBio CSO Jude Samulski Named 2020 Business Person of the Year by Triangle Business Journal - December 11th, 2020
- Tauriga Sciences Inc. Commences Development of Vegan, CBD Infused Pet Treat - December 11th, 2020
- Exodus Effect Review - CBD Oil launched – Product Review by Mike Vaughn - December 11th, 2020
- Cronos Group Inc. to Present at the MKM Partners Virtual Conference - December 11th, 2020
- Golden Leaf Holdings Applauds the Historic Passing of the MORE Act - December 11th, 2020
- Centers for Medicare & Medicaid Services Creates New Codes That Establish Specific Payment for Intravascular Lithotripsy Performed Below the Knee - December 5th, 2020
- Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in Israel - December 5th, 2020
- 22nd Century Group to Present at 13th Annual LD Micro Main Event Conference - December 5th, 2020
- Zynerba Pharmaceuticals Presents New Data in Two Posters at the 2020 Annual Meeting of the American Epilepsy Society (AES) - December 5th, 2020
- Valneva - Déclaration d’actions et de droits de vote – NOVEMBRE 2020 - December 5th, 2020
- Tauriga Sciences Inc. to Further Expand its Product Offerings With Dark Chocolate [20mg] CBD Infused Round Medallions - December 5th, 2020
- Novartis announces first data from REACH3 trial showing Jakavi® (ruxolitinib) significantly improved outcomes in patients with... - December 5th, 2020
- Virbac : Declaration of the number of shares and voting rights 11/2020 - December 5th, 2020
- Galapagos increases share capital through subscription right exercises - December 5th, 2020
- Anpac Bio Announces Change of Auditor - December 5th, 2020
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 5th, 2020
- Novartis analyses confirm benefit of Kymriah® with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas - December 5th, 2020
- Fulcrum Therapeutics Presents Updated Data on Sickle Cell Disease Program at the 62nd American Society of Hematology (ASH) Annual Meeting and... - December 5th, 2020
- Editas Medicine Announces Preclinical Data and Large-Scale Manufacturing Process for EDIT-301, in Development for the Treatment of Sickle Cell Disease... - December 5th, 2020
- Intellia Therapeutics Presents New Preclinical Data Supporting Its CRISPR/Cas9-Engineered TCR-T Cell Treatment for Acute Myeloid Leukemia at the... - December 5th, 2020
- Allogene Therapeutics Reports Positive Initial Results from Phase 1 UNIVERSAL Study of ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory... - December 5th, 2020
- CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology... - December 5th, 2020
- Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 at American Society of Hematology Annual Meeting - December 5th, 2020
- Roche announces new data reinforcing the long-term benefit of Venclexta/Venclyxto-based combination for people with relapsed or refractory chronic... - December 5th, 2020
- IGM Biosciences Presents First Clinical Data from IGM-2323 in Non-Hodgkin’s Lymphoma at 2020 ASH Annual Meeting - December 5th, 2020
- BioAge Raises $90M to Treat Aging and Age-related Diseases - December 4th, 2020
- Pandion Therapeutics Appoints Katina Dorton to its Board of Directors - December 4th, 2020
- CytomX Therapeutics to Present Updates on CX-2009 at 2020 San Antonio Breast Cancer Symposium - December 4th, 2020
- Innate Pharma to present additional efficacy data for monalizumab in combination with cetuximab in head and neck cancer at the ESMO immuno-oncology... - December 4th, 2020
- Syneos Health and ConcertAI Announce Strategic Collaboration to Accelerate the Use of Real World Evidence and AI to Advance Oncology Research - December 4th, 2020
- Taconic Biosciences Expands Innovative ExpressMODEL® Portfolio - December 4th, 2020
- Parexel Named Best Contract Research Organization by Scrip - December 4th, 2020
- AXIM® Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19 and Applies for Patent; Company’s Fourth COVID-19... - December 4th, 2020
- Intrivo Diagnostics Inks National Distribution Agreements with Concordance Healthcare Solutions and NDC for Access Bio CareStart™ COVID-19 Tests - December 4th, 2020
- Annovis Bio to Present at the New York Academy of Sciences’ Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020 Virtual Conference - December 4th, 2020
- Akari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Treatment of Uveitis and Retinal... - December 4th, 2020
- Tauriga Sciences, Inc. Introduces its Product Line of CBD Infused Bath Bombs Under the Tauri-Gum Brand - December 4th, 2020
- Genmab Announces that Janssen has Submitted a Biologics License Application to U.S. FDA for Amivantamab in Non-small Cell Lung Cancer - December 4th, 2020
- OSE Immunotherapeutics and Nantes University Hospital Announce Initiation of a Phase 1/2 Clinical Trial to Evaluate CD28 Antagonist FR104 in Patients... - December 4th, 2020
- Issuance of a 4th tranche of €1.5 million of notes convertible into new shares - December 4th, 2020
- Tauriga Sciences Inc. Fully Repays and Retires $88,333.00 Face Value 8.00% Convertible Debenture Issued on May 18, 2020 - December 4th, 2020
- Catalyst Biosciences Hosting Research & Development Call on Systemic Complement Regulator Programs - December 4th, 2020
- Indus Holdings, Inc. Announces Updated Fourth Quarter Guidance - December 4th, 2020
- ERYTECH Announces Conference Webcast to Discuss Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia to be Presented at the American... - December 4th, 2020
- BioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients - December 4th, 2020